Eiger BioPharmaceuticals Inc banner

Eiger BioPharmaceuticals Inc
F:72C1

Watchlist Manager
Eiger BioPharmaceuticals Inc Logo
Eiger BioPharmaceuticals Inc
F:72C1
Watchlist
Price: 6.18 EUR Market Closed
Market Cap: €322.3k

Wall St Price Targets

72C1 Price Targets Summary
Eiger BioPharmaceuticals Inc

There are no price targets for 72C1.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Eiger BioPharmaceuticals Inc Competitors:
Price Targets
SUPN
Supernus Pharmaceuticals Inc
44% Upside

Revenue
Forecast

N/A
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
N/A
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

The compound annual growth rate for Revenue over the next 3 years is 31%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Eiger BioPharmaceuticals Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Eiger BioPharmaceuticals Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Eiger BioPharmaceuticals Inc
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 72C1's stock price target?
Not Available

72C1 does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Eiger BioPharmaceuticals Inc?
Projected CAGR
31%

The compound annual growth rate for Revenue over the next 3 years is 31%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett